A combination of untargeted and targeted metabolomics approaches unveils changes in the kynurenine pathway following cardiopulmonary resuscitation

Metabolomics

Volumn 9, Issue 4, 2013, Pages 839-852

  Brunelli, Laura ^a   Ristagno, Giuseppe ^a   Bagnati, Renzo ^a   Fumagalli, Francesca ^a   Latini, Roberto ^a   Fanelli, Roberto ^a   Pastorelli, Roberta ^a  

^a MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

Author keywords

Cardiac arrest; Kynurenines pathway; LC MRM MS; LC MS; Plasma metabolomics; Resuscitation

Indexed keywords

3 HYDROXYANTHRANILIC ACID; 5 HYDROXYINDOLEACETIC ACID; KYNURENIC ACID; KYNURENINE; TRYPTOPHAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CATABOLISM; CENTRAL NERVOUS SYSTEM DISEASE; CONTROLLED STUDY; DISEASE SEVERITY; HEART ARREST; HEART EJECTION FRACTION; HEART HEMODYNAMICS; HEART STROKE VOLUME; LIQUID CHROMATOGRAPHY; MALE; MASS SPECTROMETRY; METABOLOMICS; NONHUMAN; PROTEIN BLOOD LEVEL; PROTEIN FUNCTION; PROTEIN STRUCTURE; RAT; RESUSCITATION; SIGNAL TRANSDUCTION;

RATTUS;

EID: 84880603709     PISSN: 15733882     EISSN: 15733890     Source Type: Journal    
DOI: 10.1007/s11306-013-0506-0     Document Type: Article

References (69)

1. Abramson, N. S. (1991). A randomized clinical study of a calcium-entry blocker (lidoflazine) in the treatment of comatose survivors of cardiac arrest. Brain Resuscitation Clinical Trial II Study Group. New England Journal of Medicine, 324, 1225-1231.
2. Adams Wilson, J. R., Morandi, A., Girard, T. D., et al. (2012). The association of the kynurenine pathway of tryptophan metabolism with acute brain dysfunction during critical illness. Critical Care Medicine, 40, 835-841.
3. Alexander, D., Lombardi, R., Rodriguez, G., Mitchell, M. M., & Marian, A. J. (2011). Metabolomic distinction and insights into the pathogenesis of human primary dilated cardiomyopathy. European Journal of Clinical Investigation, 41, 527-538.
4. Andine, P., Lehmann, A., Ellren, K., et al. (1988). The excitatory amino acid antagonist kynurenic acid administered after hypoxic-ischemia in neonatal rats offers neuroprotection. Neuroscience Letters, 90, 208-212.
5. Baranowski, M., & Gorski, J. (2011). Heart sphingolipids in health and disease. Advances in Experimental Medicine and Biology, 721, 41-56.
6. Barderas, M. G., Laborde, C. M., Posada, M., et al. (2011). Metabolomic profiling for identification of novel potential biomarkers in cardiovascular diseases. Journal of Biomedicine and Biotechnology, 2011, 790132.
7. Braidy, N., Grant, R., Brew, B. J., et al. (2009). Effects of kynurenine pathway metabolites on intracellular NAD synthesis and cell death in human primary astrocytes and neurons. International Journal of Tryptophan Research, 2, 61-69.
8. Brouns, R., Verkerk, R., Aerts, T., et al. (2010). The role of tryptophan catabolism along the kynurenine pathway in acute ischemic stroke. Neurochemical Research, 35, 1315-1322.
9. Brown, C. G., Martin, D. R., Pepe, P. E., et al. (1992). A comparison of standard-dose and high-dose epinephrine in cardiac arrest outside the hospital. The Multicenter High-Dose Epinephrine Study Group. New England Journal of Medicine, 327, 1051-1055.
10. Changsirivathanathamrong, D., Wang, Y., Rajbhandari, D., et al. (2011). Tryptophan metabolism to kynurenine is a potential novel contributor to hypotension in human sepsis. Critical Care Medicine, 39, 2678-2683.
11. Chen, Y., & Guillemin, G. J. (2009). Kynurenine pathway metabolites in humans: disease and healthy states. International Journal of Tryptophan Research, 2, 1-19.
12. Chen, Y., Stankovic, R., Cullen, K. M., et al. (2010). The kynurenine pathway and inflammation in amyotrophic lateral sclerosis. Neurotoxicity Research, 18, 132-142.
13. Chugh, S. S., Jui, J., Gunson, K., et al. (2004). Current burden of sudden cardiac death: multiple source surveillance versus retrospective death certificate-based review in a large U. S. community. Journal of the American College of Cardiology, 44, 1268-1275.
14. Darlington, L. G., Mackay, G. M., Forrest, C. M., et al. (2007). Altered kynurenine metabolism correlates with infarct volume in stroke. European Journal of Neuroscience, 26, 2211-2221.
15. Dezfulian, C., Raat, N., Shiva, S., & Gladwin, M. T. (2007). Role of the anion nitrite in ischemia-reperfusion cytoprotection and therapeutics. Cardiovascular Research, 75, 327-338.
16. Frangogiannis, N. G., Youker, K. A., Rossen, R. D., et al. (1998). Cytokines and the microcirculation in ischemia and reperfusion. Journal of Molecular and Cellular Cardiology, 30, 2567-2576.
17. Fukui, S., Schwarcz, R., Rapoport, S. I., Takada, Y., & Smith, Q. R. (1991). Blood-brain barrier transport of kynurenines: implications for brain synthesis and metabolism. Journal of Neurochemistry, 56, 2007-2017.
18. Fukui, M., Tanaka, M., Toda, H., et al. (2012). High plasma 5-hydroxyindole-3-acetic acid concentrations in subjects with metabolic syndrome. Diabetes Care, 35, 163-167.
19. Fukushima, T., Sone, Y., Mitsuhashi, S., Tomiya, M., & Toyo'oka, T. (2009). Alteration of kynurenic acid concentration in rat plasma following optically pure kynurenine administration: a comparative study between enantiomers. Chirality, 21, 468-472.
20. Goldstein, L. E., Leopold, M. C., Huang, X., et al. (2000). 3-Hydroxykynurenine and 3-hydroxyanthranilic acid generate hydrogen peroxide and promote alpha-crystallin cross-linking by metal ion reduction. Biochemistry, 39, 7266-7275.
21. Griffin, J. L., Atherton, H., Shockcor, J., & Atzori, L. (2011). Metabolomics as a tool for cardiac research. Nature Reviews Cardiology, 8, 630-643.
22. Gulaj, E., Pawlak, K., Bien, B., & Pawlak, D. (2010). Kynurenine and its metabolites in Alzheimer's disease patients. Advances in Medical Sciences, 55, 204-211.
23. Hilmas, C., Pereira, E. F., Alkondon, M., et al. (2001). The brain metabolite kynurenic acid inhibits alpha7 nicotinic receptor activity and increases non-alpha7 nicotinic receptor expression: physiopathological implications. Journal of Neuroscience, 21, 7463-7473.
24. Jaswal, J. S., Keung, W., Wang, W., Ussher, J. R., & Lopaschuk, G. D. (2011). Targeting fatty acid and carbohydrate oxidation: a novel therapeutic intervention in the ischemic and failing heart. Biochimica et Biophysica Acta, 1813, 1333-1350.
25. Jung, I. D., Lee, M. G., Chang, J. H., et al. (2009). Blockade of indoleamine 2, 3-dioxygenase protects mice against lipopolysaccharide-induced endotoxin shock. Journal of Immunology, 182, 3146-3154.
26. Knapp, M. (2011). Cardioprotective role of sphingosine-1-phosphate. Journal of Physiology and Pharmacology, 62, 601-607.
27. Knapp, M., Baranowski, M., Czarnowski, D., et al. (2009). Plasma sphingosine-1-phosphate concentration is reduced in patients with myocardial infarction. Medical Science Monitor, 15, CR490-CR493.
28. Krause, G. S., Kumar, K., White, B. C., Aust, S. D., & Wiegenstein, J. G. (1986). Ischemia, resuscitation, and reperfusion: mechanisms of tissue injury and prospects for protection. American Heart Journal, 111, 768-780.
29. Krismer, A. C., Dunser, M. W., Lindner, K. H., et al. (2006). Vasopressin during cardiopulmonary resuscitation and different shock states: a review of the literature. American Journal of Cardiovascular Drugs, 6, 51-68.
30. Lebuffe, G., Schumacker, P. T., Shao, Z. H., et al. (2003). ROS and NO trigger early preconditioning: relationship to mitochondrial KATP channel. American Journal of Physiology Heart and Circulatory Physiology, 284, H299-H308.
31. Levraut, J., Iwase, H., Shao, Z. H., Vanden Hoek, T. L., & Schumacker, P. T. (2003). Cell death during ischemia: relationship to mitochondrial depolarization and ROS generation. American Journal of Physiology Heart and Circulatory Physiology, 284, H549-H558.
32. Lewis, G. D., Wei, R., Liu, E., et al. (2008). Metabolite profiling of blood from individuals undergoing planned myocardial infarction reveals early markers of myocardial injury. Journal of Clinical Investigation, 118, 3503-3512.
33. Locasale, J. W., Melman, T., Song, S., et al. (2012). Metabolomics of human cerebrospinal fluid identifies signatures of malignant glioma. Molecular and Cellular Proteomics, 11(6), M111.
34. Lopaschuk, G. D., Ussher, J. R., Folmes, C. D., Jaswal, J. S., & Stanley, W. C. (2010). Myocardial fatty acid metabolism in health and disease. Physiological Reviews, 90, 207-258.
35. Lopez, A. S., Alegre, E., Diaz-Lagares, A., et al. (2008). Effect of 3-hydroxyanthranilic acid in the immunosuppressive molecules indoleamine dioxygenase and HLA-G in macrophages. Immunology Letters, 117, 91-95.
36. Mandi, Y., & Vecsei, L. (2012). The kynurenine system and immunoregulation. Journal of Neural Transmission, 119, 197-209.
37. Mayr, M., Liem, D., Zhang, J., et al. (2009). Proteomic and metabolomic analysis of cardioprotection: interplay between protein kinase C epsilon and delta in regulating glucose metabolism of murine hearts. Journal of Molecular and Cellular Cardiology, 46, 268-277.
38. Mayr, M., Yusuf, S., Weir, G., et al. (2008). Combined metabolomic and proteomic analysis of human atrial fibrillation. Journal of the American College of Cardiology, 51, 585-594.
39. Meybohm, P., Gruenewald, M., Albrecht, M., et al. (2009). Hypothermia and postconditioning after cardiopulmonary resuscitation reduce cardiac dysfunction by modulating inflammation, apoptosis and remodeling. PLoS ONE, 4, e7588.
40. Midttun, O., Hustad, S., & Ueland, P. M. (2009). Quantitative profiling of biomarkers related to B-vitamin status, tryptophan metabolism and inflammation in human plasma by liquid chromatography/tandem mass spectrometry. Rapid Communications in Mass Spectrometry, 23, 1371-1379.
41. Morita, T., Saito, K., Takemura, M., et al. (2001). 3-Hydroxyanthranilic acid, an l-tryptophan metabolite, induces apoptosis in monocyte-derived cells stimulated by interferon-gamma. Annals of Clinical Biochemistry, 38, 242-251.
42. Myint, A. M. (2012). Kynurenines: from the perspective of major psychiatric disorders. FEBS Journal, 279, 1375-1385.
43. Neglia, D., De Caterina, A., Marraccini, P., et al. (2007). Impaired myocardial metabolic reserve and substrate selection flexibility during stress in patients with idiopathic dilated cardiomyopathy. American Journal of Physiology Heart and Circulatory Physiology, 293, H3270-H3278.
44. Nolan, J. P., Soar, J., Zideman, D. A., et al. (2010). European resuscitation council guidelines for resuscitation 2010 section 1. Executive summary. Resuscitation, 81, 1219-1276.
45. Nordstrom, A., & Lewensohn, R. (2010). Metabolomics: moving to the clinic. Journal of Neuroimmune Pharmacology, 5, 4-17.
46. Nordstrom, A., Want, E., Northen, T., Lehtio, J., & Siuzdak, G. (2008). Multiple ionization mass spectrometry strategy used to reveal the complexity of metabolomics. Analytical Chemistry, 80, 421-429.
47. Nozaki, K., & Beal, M. F. (1992). Neuroprotective effects of l-kynurenine on hypoxia-ischemia and NMDA lesions in neonatal rats. Journal of Cerebral Blood Flow and Metabolism, 12, 400-407.
48. Ouyang, Y. B., Tan, Y., Comb, M., et al. (1999). Survival- and death-promoting events after transient cerebral ischemia: phosphorylation of Akt, release of cytochrome C and activation of caspase-like proteases. Journal of Cerebral Blood Flow and Metabolism, 19, 1126-1135.
49. Pawlak, D., Tankiewicz, A., & Buczko, W. (2001). Kynurenine and its metabolites in the rat with experimental renal insufficiency. Journal of Physiology and Pharmacology, 52, 755-766.
50. Reinhard, J. F., Jr. (2004). Pharmacological manipulation of brain kynurenine metabolism. Annals of the New York Academy of Sciences, 1035, 335-349.
51. Rhee, E. P., & Gerszten, R. E. (2012). Metabolomics and cardiovascular biomarker discovery. Clinical Chemistry, 58, 139-147.
52. Sabatine, M. S., Liu, E., Morrow, D. A., et al. (2005). Metabolomic identification of novel biomarkers of myocardial ischemia. Circulation, 112, 3868-3875.
53. Sans, S., Kesteloot, H., & Kromhout, D. (1997). The burden of cardiovascular diseases mortality in Europe. Task Force of the European Society of Cardiology on Cardiovascular Mortality and Morbidity Statistics in Europe. European Heart Journal, 18, 1231-1248.
54. Shah, S. H., Bain, J. R., Muehlbauer, M. J., et al. (2010). Association of a peripheral blood metabolic profile with coronary artery disease and risk of subsequent cardiovascular events. Cardiology and Cardiovascular Genetics, 3, 207-214.
55. Siassi, F., Wang, M., Kopple, J. D., & Swendseid, M. E. (1977). Plasma tryptophan levels and brain serotonin metabolism in chronically uremic rats. Journal of Nutrition, 107, 840-845.
56. Stone, T. W. (1993). Neuropharmacology of quinolinic and kynurenic acids. Pharmacological Reviews, 45, 309-379.
57. Stoy, N., Mackay, G. M., Forrest, C. M., et al. (2005). Tryptophan metabolism and oxidative stress in patients with Huntington's disease. Journal of Neurochemistry, 93, 611-623.
58. Sun, S., Tang, W., Song, F., et al. (2010). The effects of epinephrine on outcomes of normothermic and therapeutic hypothermic cardiopulmonary resuscitation. Critical Care Medicine, 38, 2175-2180.
59. Turer, A. T., Stevens, R. D., Bain, J. R., et al. (2009). Metabolomic profiling reveals distinct patterns of myocardial substrate use in humans with coronary artery disease or left ventricular dysfunction during surgical ischemia/reperfusion. Circulation, 119, 1736-1746.
60. Vakeva, A. P., Agah, A., Rollins, S. A., et al. (1998). Myocardial infarction and apoptosis after myocardial ischemia and reperfusion: role of the terminal complement components and inhibition by anti-C5 therapy. Circulation, 97, 2259-2267.
61. Wang, Z., Klipfell, E., Bennett, B. J., et al. (2011a). Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease. Nature, 472, 57-63.
62. Wang, T. J., Larson, M. G., Vasan, R. S., et al. (2011b). Metabolite profiles and the risk of developing diabetes. Nature Medicine, 17, 448-453.
63. Wang, Y., Liu, H., McKenzie, G., et al. (2010). Kynurenine is an endothelium-derived relaxing factor produced during inflammation. Nature Medicine, 16, 279-285.
64. Wang, J., Simonavicius, N., Wu, X., et al. (2006). Kynurenic acid as a ligand for orphan G protein-coupled receptor GPR35. Journal of Biological Chemistry, 281, 22021-22028.
65. Wonodi, I., Stine, O. C., Sathyasaikumar, K. V., et al. (2011). Downregulated kynurenine 3-monooxygenase gene expression and enzyme activity in schizophrenia and genetic association with schizophrenia endophenotypes. Archives of General Psychiatry, 68, 665-674.
66. Xia, J., & Wishart, D. S. (2011). Web-based inference of biological patterns, functions and pathways from metabolomic data using MetaboAnalyst. Nature Protocols, 6, 743-760.
67. Zadori, D., Klivenyi, P., Vamos, E., et al. (2009). Kynurenines in chronic neurodegenerative disorders: future therapeutic strategies. Journal of Neural Transmission, 116, 1403-1409.
68. Zhao, G., Jeoung, N. H., Burgess, S. C., et al. (2008). Overexpression of pyruvate dehydrogenase kinase 4 in heart perturbs metabolism and exacerbates calcineurin-induced cardiomyopathy. American Journal of Physiology Heart and Circulatory Physiology, 294, H936-H943.
69. Zheng, X., Kang, A., Dai, C., et al. (2012). Quantitative analysis of neurochemical panel in rat brain and plasma by liquid chromatography-tandem mass spectrometry. Analytical Chemistry, 84, 10044-10051.